AdductNE, LLC
AdductNE is a radiopharmaceutical company spun-out from the University of Nebraska Medical Center (UNMC) in 2019. AdductNE is dedicated to developing targeted imaging and therapeutic agents for cancer.
-
Jered Christopher Garrison, PhD
President & Chief Scientific Officer
-
Shana Garrison, PhD
Chief Financial Officer
HDAX Therapeutics
HDAX Therapeutics is developing a targeted therapeutics platform for the safe and efficacious treatment of HDAC-driven pathologies such as neuropathies and cancers by rationally designing therapies to overcome common drug challenges including weak binding, off-target toxicities, and poor pharmacokinetic profiles.
-
Nabanita Nawar, PhD
Chief Executive Officer
-
Pimyupa Manaswiyoungkul, PhD
Chief Operations Officer
-
Olasunkanmi Olaoye, PhD
Vice President Drug Discovery
-
Elvin de Araujo, PhD
Chief Innovation Officer
-
Patrick Gunning, PhD
Scientific Advisor
Hybridex Biosciences
Hybridex Biosciences is an early-stage biotech company aiming to enable the next-generation of safe gene editing. Using its tunable antisense nucleic acid platform, developed in labs at Yale University, Hybridex aims to improve the safety and control of CRISPR-based systems to realize the full potential of gene editing therapeutics.
-
Jem Atillasoy, MD
Candidate, Co-founder
-
Nicholas Economos, MD/PhD
Candidate, Co-founder
Jenthera Therapeutics, Inc
Jenthera Therapeutics is a preclinical biotechnology company leveraging a novel non-viral, non-lipid CRISPR platform for the development of groundbreaking therapeutics. The platform presents tissue-specific delivery, built-in safety, and advanced gene correction capabilities, proposing to unlock new realms of therapeutic possibilities and allow for the development of complex multi-loci corrective gene therapies.
-
Dr. Philip Roche
Chief Executive Officer, Chief Scientific Officer
-
Laurent D. Ziri, CPA-CA
Chief Operations Officer
-
Sandra Azoulay, CPA-CA
Chief Financial Officer, Communications
PacDNA LLC
PacDNA is an oligonucleotide therapeutics company that will expand the horizon of this drug modality to include previously inaccessible organs and tissues. Its proprietary oligonucleotide enhancer technology will be a new drug production engine, producing more potent clinical leads with fewer side effects at a lower cost.
-
Chad A. Mirkin, PhD
Professor
-
Ke Zhang, PhD
Chief Executive Officer & Professor
Orion Therapeutics
Orion Therapeutics has developed a patented lipid-based nanoparticle capable of safe, effective, and targeted delivery of RNA medicine to diseased tissues to address the delivery barrier to successful gene therapy. This technology will be licensed to pharmaceutical partners to facilitate success of RNA therapeutics and vaccine programs.
-
Trey Fisher, PhD
Co-founder & Chief Executive Officer
-
Michael McCaman, PhD
Co-founder, President, Director of Strategic Planning
-
Deidra Mountain
Co-founder, Director of Vascular Therapeutics Pipeline
-
Jennifer Zachry
Co-founder, Director of Business Development
Artificial Axon Labs Inc.
Artificial Axon Labs is developing a transformational drug discovery platform to discover medicines for neurodegenerative diseases. Our technology, developed by the company founders at MIT, combines novel biocompatible materials, state-of-the-art 3D printing of axon mimics (Artificial Axons), and patient-derived human cells to generate first-in-class remyelinating drugs for Multiple Sclerosis.
-
Anna Jagielska, PhD
President, CEO, CSO, & Co-Founder
-
Kavin Kowsari
Vice President, CTO, & Co-Founder
Atorvia Health Technologies
Atorvia’s purpose is to transform outcomes for patients with severe medical conditions. Our initial focus is acute kidney injury (AKI), a devastating condition which affects millions worldwide yet still lacks effective therapy. To address this crisis, we are developing a kidney-targeted peptide that prevents regulated cell death and kidney failure.
-
Jane Lapon
CEO
-
David Allinson
CFO & Head of Business Development
-
Nermeen Varawalla MD
Chair Clinical Advisory Group
-
Steven C. Borkan MD
Associate Professor, Boston Medical Centre
Modulari-T Biosciences
Modulari-T is a preclinical stage immunotherapy startup developing a novel platform, the MARC, to reprogram immune cells for oncology and beyond. Our MARC technology is twice as potent as CAR-T while reducing side-effects ten-fold which will enable adoptive cell therapy to break-in to new indications in autoimmunity and regenerative medicine.
-
David Cotnoir-White, PhD
CEO & Co-Founder
-
Étienne Gagnon, PhD
CSO & Co-Founder
PhenoTarget Biosciences, Inc.
PhenoTarget Biosciences, Inc. is a biotech startup focused on the discovery and development of first-in-class therapies for unmet medical needs including oncology, fibrosis, cardiovascular diseases and infectious diseases. We are modality agnostic that our pipeline and technology platforms span small molecules to functionalized peptides and next generation cell therapies.
-
Shoutian Zhu, PhD
CEO
-
Wenshe Liu, PhD
CSO
-
James Schaeffer, PhD
CBO
SYTE.bio Inc.
SYTE.bio is an early-stage synthetic biology company focused on the discovery, development and future commercialization of precision therapeutics using its proprietary Linear DNA and Circular RNA technology platforms. SYTE.bio aims to deliver novel and effective therapeutics and vaccines enabling precise corrective and preventive treatments for patients worldwide.
-
Martin Williams
Founder & CEO